Biogen Idec News
Most Popular Biogen Idec Story
Tysabri label change could add $1B to sales
Biogen Idec ($BIIB) has pulled off a big coup in personalized medicine. The multiple sclerosis drug Tysabri has long been weighed down by a well-known safety risk: It's linked with a potentially Read more...
Latest Headlines
- January 23, 2012
- September 6, 2011
- August 16, 2011
- May 20, 2011
- April 27, 2011
- April 25, 2011
- April 21, 2011
- January 21, 2011
- January 12, 2011
- December 22, 2010
- December 17, 2010
- November 3, 2010
- October 27, 2010
- April 8, 2010
- March 29, 2010
- March 25, 2010
- March 23, 2010
- March 22, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
